OFEV^®
(nintedanib)

time to face
IPF head on

SSc-ILD: From Skin to lung. The Scencis implications

Document ID: PC-ZA-101810

21/09/2022

Author: Boehringer Ingelheim

Prof Vanessa Smith discusses the Scencis trial, Treatment of patients with SSc-ILD and Why thinking lung is important (Edited Recording 25 min)

RELATED CONTENT

PC-ZA-101810
Production date: September 2022

Redirected Link

2024-08-24